Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515589 | 0.85 | CYP2D6 (0.40) | CYP3A4CYP2C19ALDH1A1LMNAKCNA5 | |
| Cadaverine Tartrate SCHEMBL16685626 | 0.76 | LMNA (0.44) | CYP3A4TSHRALDH1A1LMNAMEN1 | |
| SCHEMBL14773209 | 0.73 | CYP3A4 (0.61) | CYP3A4TSHRCYP2C19ALDH1A1LMNA | |
| SCHEMBL16685702 | 0.70 | TP53 (0.51) | TSHRCYP2C19ALDH1A1LMNAMEN1 | |
| SCHEMBL19881633 | 0.70 | ALDH1A1 (0.47) | CYP3A4TSHRCYP2C19ALDH1A1LMNA | |
| SCHEMBL469061 | 0.69 | MEN1 (0.51) | ALDH1A1LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL16271009 | 0.69 | ALDH1A1 (0.46) | CYP3A4TSHRCYP2C19ALDH1A1LMNA | |
| SCHEMBL16685629 | 0.68 | LMNA (0.39) | CYP3A4TSHRALDH1A1LMNAMEN1 | |
| SCHEMBL12262583 | 0.68 | THRB (0.53) | CYP3A4TSHRALDH1A1LMNAADRA2A | |
| SCHEMBL9870121 | 0.68 | ADRA2A (0.50) | ALDH1A1LMNAADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056487-B1 | SYNTHESIS OF ENONE INTERMEDIATE | HARVARD COLLEGE (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3056487-A1 | SYNTHESIS OF ENONE INTERMEDIATE | President and Fellows of Harvard College (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487160-B1 | Synthesis of Enone Intermediate | HARVARD COLLEGE (US) | 2016-02-03 | — | — | EP | disclosed |
| US-8907104-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2479169-B1 | Synthesis of Enone Intermediate | HARVARD COLLEGE (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-8580969-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130217886-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2076133-B1 | SYNTHESIS OF ENONE INTERMEDIATE | HARVARD COLLEGE (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8293920-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2487160-A1 | Synthesis of Enone Intermediate | President and Fellows of Harvard College (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2479169-A1 | Synthesis of Enone Intermediate | President and Fellows of Harvard College (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-7960559-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | MYERS ANDREW G | 2011-01-13 | — | — | US | disclosed |
| US-7763735-B2 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-27 | — | — | US | disclosed |
| EP-2076133-A2 | SYNTHESIS OF ENONE INTERMEDIATE | The President and Fellows of Harvard College (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-09 | — | — | US | disclosed |
| WO-2008127361-A2 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217886-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | CYP3A4 359/4885TSHR 1429/4885CYP2C19 365/4885 |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | CYP3A4 359/4885TSHR 1429/4885CYP2C19 365/4885 |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | TECR, TSN, TARS2 | CYP3A4 552/4885TSHR 1065/4885CYP2C19 553/4885 |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | CYP3A4 359/4885TSHR 1429/4885CYP2C19 365/4885 |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | CYP3A4 359/4885TSHR 1429/4885CYP2C19 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.